化学科研者一站式服务平台
-
利昔伐坦; 利伐普坦
N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide
化合物简介
Lixivaptan (VPA-985) is a phase III pharmaceutical being developed by Cardiokine, Inc., a specialty pharmaceutical company based in Philadelphia, PA, focused on the development of pharmaceuticals for the treatment and prevention of cardiovascular diseases. Lixivaptan is, as of May 2010, in Phase III clinical trials involving patients with hyponatremia, including those with concomitant heart failure. Hyponatremia is an electrolyte disturbance in which the sodium concentration in the serum is lower than normal. Lixivaptan may help some patients eliminate excess fluids while retaining electrolytes.
基本信息
CAS：168079-32-1
中文别名：
英文别名：Lixivaptan;UNII-8F5X4B082E;WAY-VPA-985;VPA-985;
分子式：C27H21ClFN3O2
分子量：473.926
精确质量：473.131
Psa：57.83
Logp：6.499
中文别名：
英文别名：Lixivaptan;UNII-8F5X4B082E;WAY-VPA-985;VPA-985;
分子式：C27H21ClFN3O2
分子量：473.926
精确质量：473.131
Psa：57.83
Logp：6.499
编号系统
UNII：8F5X4B082E
物化性质
密度：1.32g/cm3
沸点：626.5ºC at 760mmHg
闪点：332.7ºC
折射率：1.657
蒸汽压：1.3E-15mmHg at 25°C
沸点：626.5ºC at 760mmHg
闪点：332.7ºC
折射率：1.657
蒸汽压：1.3E-15mmHg at 25°C
安全信息
生产方法及用途
合成路线
上游原料
下游产品
图谱
13C NMR : Predict
1H NMR : Predict
